Home | Objectives | Organization | Members | News and Info. | Publications | Products | Interesting Links | Library | Secure |
|
|
ACTIP
Bulletin 34 |
|
|
Next meeting Please note that the next ACTIP meeting will take place in Montreux, Switzerland December 11-12, 2003
The meeting will be hosted by company Serono. For non-members: please contact the:actip@wirehub.nl ACTIP Secretariat if you would like to receive an invitation and accompanying documentation
In this issue Call for International Treaty on scientific exchange SME's a MUST in most EU FP6 projects Russians i n FP6, and their networks as an example? Action plan for 3% target R&D programme on HIV/AIDS , malaria and tuberculosis Directive o n cells and tissues available Candidate countries pro animal experiments Public opinion on biotechnology
ACTIP website
The ACTIP website remains hugely successful. Here are some statistics: in February 2003, the homepage received 22,066 hits, with 4,187 specific requests for pages. The most popular pages were interesting links, members, monoclonal antibodies and bulletin 32, but in fact all pages and files receive between 50-200 visits per month. Of the visitors, 45% have an industry address. More than 17,000 visitors directly link onto the homepage, while only a minority arrives there through a search machine such as google or yahoo. In the months of March and April similar patterns were seen. Call for international treaty on scientific exchangeA prominent US law professor from Stanford University has called for an international treaty on sharing scientific and technological information, to be based on the arrangements already agreed for free trade under the World Trade Organisation (WTO) system. John Barton, who is also chair of the international commission on intellectual property, claimed in a recent presentation to the United Nations conference on trade and development that scientific progress requires the sharing of information, and that this collaboration is being hindered. "Science and technology require a commons of data, ideas and insight. Everyone benefits from the openness of that commons. A scientist or engineer is more effective if he or she has access to the work of predecessors [...]. Exchange of data and scientific communication across border is not only part of the mythology of science; it also contributes to the rate of progress of science and technology," said Professor Barton. Professor Barton believes that the exchange of information is being restricted by three things: national protectionism, the expansion of intellectual property protection and the lack of contact between scientists from developing countries and the rest of the world. "The world as a whole loses," he said. The solution, according to Professor Barton, is an international treaty, under which countries would make their subsidies and data available in return for the same gesture by other countries. This is also the philosophy behind the WTO agreement. "As with free trade, the net benefits are positive, for a more inclusive and open global scientific/technological commons will be more dynamic. To do this requires a treaty that defines rules freeing scientific/technological exchange and establishes procedures for negotiating regular improvements and expansions of those rules," explained Professor Barton. The whole world would benefit from such cooperation, said the professor, quoting EU Research Commissioner Philippe Busquin, who has argued that the European Research Area 'must be opened up to the rest of the world. This openness should enable EU countries to benefit from international cooperation in science and technology, paving the way for closer political and economic relations with third countries.' In addition to provisions securing equal access to scientific and technological support and capability, such a treaty could also ensure that the benefits of publicly funded research are available to all, and not only those in whose country the research was conducted, Professor Barton elaborated. He also suggested that the agreement could override restrictions preventing students from studying in other countries and researchers from gain experience abroad. He also proposed balanced safeguard provisions in such a treaty in order to ensure that intellectual property rights are managed in a fair way and to protect national security. "For a treaty with a global scientific focus, there are two reasonable negotiating fora. One is UNESCO, the United Nations Educational, Scientific and Cultural Organisation. This might be a good place to begin, but is certainly more scientific than technological. The better forum for the more technological issues, and possible for all issues, is the WTO," argued Professor Barton. Source: CORDIS RTD News, April 24, 2003 On the web
New Biosociety web page The Research DG of the European Commission has implemented the new Biosociety web site: europa.eu.int/comm/research/biosociety/index_en.htm' This website aims primarily at stimulating interactions between biotech researchers and social scientists, economists and ethical experts active in the field of life sciences. It also informs and opens a dialogue with interested citizens on relevant European policies and research activities.
International Federation of Animal Health The International Federation of Animal health has a new website:
News from the CommissionSME's a MUST in most EU FP6 projects On December 19, the Commission (Research DG &endash; Genomics & Health programme staff) organised a meeting with representatives from industry platforms, EuropaBio SME project, Innovation Relay Centres, National Focal Points, etc. They were looking for help in order to reach one of the targets set to FP6: obtain a 15% participation (in financial terms) of SME's throughout the programme. The message was clearly delivered: proper participation of SME will be an important selection criteria. Such involvement should not be superficial: the concerned enterprises should play an active and essential role in the implementation of the projects &endash; and in most cases (for Integrated Projects or Networks of Excellence) one SME might even not be enough. Having set this objective, and decided to apply this as a strict selection criteria, Commission officials are left with the need for ideas on how to achieve this ambitious target without jeopardizing the whole programme and its overall effectiveness. Participants in the meeting suggested possible leads for making the programmes more "attractive" to SME's &endash; or tools available for identifying possible candidates. The task is now with representatives from National Focal Points and Innovation Relay Centres, mostly, or industrial associations, to figure out which company should be suitable candidates in the various projects under preparation. One recommended source of information would be the "Partners for Life": this is a EU funded project and they claim to be in contact with over 40.000 SME's. The 15% SME target is also intended to apply to clinical trials ñ and the question was raised about the professionalism of newcomer SME's in this area, knowing that the number of patients available is the "limiting factor" and that there are ethical rules. One clear message to the Commission is that payments should be made more regularly in the case of SME's. Normal practice at EU level indeed requires that SME's deliver formal evidence that they are "financially healthy" before signing the contracts ñ but the start up's should not be put at risk because of financial uncertainties created by the Commission. Should you think about any other possible suggestion for the Commission please write to torbjoern.ingemansson@cec.eu.int Russians in FP6, and their networks as an example? It has been predicted that participation in the Sixth Framework Programme (FP6) will be much easier for Russian entities than in previous framework programmes. In an interview Vladimir Belokurov, Vice-Rector of Lomonosov Moscow State University, outlined how Russia had been able to participate in former framework programmes, but its researchers had not known how they should go about doing so. He added that they had also been disadvantaged by a lack of contact with EU researchers. 'In FP6, things may be easier as there is a reversed process: European scientists know the Russian experts ...they are inviting them to participate in projects in Germany, France and elsewhere.'Ý Professor Belokurov described Russian experience of EU research programmes as positive, citing ideas, calculations and methodology as the main areas where his compatriots have played a significant role. He also emphasized that basic science is still seen as important in Russia: 'Fundamental sciences are needed in every sector. It wouldn't be wise to concentrate only on industry driven initiatives.' It has been suggested that the EU could learn from Russia's internal networks, known as 'scientific schools'. These networks build strong relations between distinguished scientists from different universities and their pupils. '[They] share the same language, they collaborate on research and they transfer their knowledge to the younger generations. This powerful system has been preserved for years, despite the various socio-economic changes,' explained Professor Belokurov. For a full version of the interview with Professor Belokurov, visit www.cordis.lu/greece/press24.htm . Council on competitiveness On May 13, The EU Council met to discuss competitiveness in the European Union. While commenting on the Commission document ëStrengthening European Innovation Policy', it was stressed that: enterprises must be considered central to innovation in Europe and small firms should benefit from improved business support services; the emergence of new firms such as new technology based firms and spin offs is a strong force for innovation in many sectors and that it is these firms that often have a strong potential for growth; R&D and technology transfer are essential for long term economic growth, while recognizing that they must be accompanied by such measures to facilitate the successful exploitation of results, such as prototyping, testing and adaptation, engineering, re-engineering and demonstration; Business investment in R&D and innovation in the Union should be increased, moving towards the Barcelona objective of approaching 3% of GDP. Action plan for 3% target At the same meeting, Commissioner Busquin presented the April 30 communication ëInvesting in research: an action plan for Europe ("3% target"). The Council held a preliminary exchange of views. Discussion centered mainly on issues such as:
The Action Plan put forward by the Commission suggests some 50 new actions in research and innovation policies as well as in other policy areas. Many of the actions are geared to making Europe more attractive for private investment in R&D. The main challenge of the Barcelona objective on RTD is the raising of business contribution to the Gross Expenditure for R&D from 56% in 1999 to 67% in 2010, while total GERD/GDP will increase from 1.9 to 3% in 2010. Furthermore, the Council discussed the progress report on the 'Life Sciences and Biotechnology &endash; a strategy for Europe', presented by Commissioners Liikanen and Busquin. In the communication, the Commission sets out the progress made and anticipates emerging issues with regard to its strategy. The member states took the opportunity to discuss the priority actions taken by them, as the strategy is put into place. R&D programme on HIV/AIDS, malaria and tuberculosis The Council adopted the decision on the Community participation in a research and development programme aimed at developing new clinical interventions to combat HIV/AIDS, malaria and tuberculosis through a long-term partnership between Europe and the developing countries, undertaken by several member states (Doc 361403 and 8545/1/03 rev 1). The implementation of this action within FP6 is a novelty because of the first time application of article 169, by which the Community itself is participating in a programme undertaken by several memberstates. The vast majority of memberstates will be participating in the programme from the beginning, as well as Norway. Other states can join later if they so wish. The Community is making a financial contribution of 200 m¨ to this programme,which is added to thee stimated 200 m¨ from participating memberstates and 200 m¨ from other public and private funds. Thus, the total budget of the programme will benearing 600 m ¨. A copy of the preliminary minutes of this Councilmeeting in pdf is available on the secure part of the ACTIP website. Directive on cells and tissues available Also available on the secure part of the ACTIP website is a pdf-copy of the proposal for a directive of the European Parliament and of the Council on setting standards of quality and safety for the donation, procurement, testing, processing, storage and distribution of human tissues and cells. (2002/0128(COD). The cells covered are used for application to the human body, and the directive is meant to ensure a high level of protection of human health. The directive does not apply to tissues and cells used as an autologous graft within the same surgical procedure. Candidate countries pro animal experiments The first major European Commission survey of attitudes to science in the candidate countries was published in early April 2003, and showed interesting differences in attitudes to animal experimentation between the candidate countries and existing member states. In November 2002 sample questions were fielded to a total of 12,247 nationals in the 13 candidate countries. While people in the member states are completely divided over the issue of experiments on animals like dogs and monkeys (45% agree, 41% disapprove), the overwhelming majority of the candidate region supports such experiments (63% pro, 22% against) if they targeted human health problems. The proportion of opponents to animal experimentation was lowest in Bulgaria (only 8% disapprove). The proportion of opponents to animal experiments was comparable to the EU average only in Malta and Slovenia. Source: EBRA bulletin, Spring 2003 Public opinion on biotechnology
Eurobarometer 2002 In 1991, 1996 and 1999 the European Commission sampled the opinion of EU citizens on biotechnology. The most recent one, covering 2002, gives the result of an inquiry among 16,500 Europeans in every EU member state. A detailed summary of the results is available on: europa.eu.int/comm/public_opinion/archives/eb/ebs_177_en.pdf . The following picture emerges:
Public .. more confidence with more transgenic words? Generally, we all know what is meant with a transgenic or genetically modified organism: the organism into which hereditary (genetic) material from another organism has been introduced. These, however, are process-based terms, and they have resulted in very little appreciation for the sources, extent and novelty of genetic modifications made in GMOs. Not surprisingly, indiscriminate scientific, public and regulatory scrutiny based on misleading conceptual assumptions have developed into negative perceptions of GMOs, particularly among EU citizens. Kaare Nielsen of the University of Tromso in Norway hypothesizes that this failure to establish, from the onset, explicit terminology to categorize the various applications of gene technology in breeding have contributed to this skepticism and to rejection of the technology by many consumers. His main criticism is on the current process-based categorization of GMOs. He therefore proposes the adoption of alternative categories that would shift focus to a product-based perception of gene technology. Accordingly, he arrives at five categories of GMOs as defined by their biological relevance which also address ethical, religious and public concerns. The proposed terms permit a more precise communication of the sources of genetic variability used in gene technology based upon breeding. When reading the article, I had this ëof course' experience (or Aha-erlebnis), and personally (HH) I would be pleased if we could see some of these terms in communications about GMOs. So here are the terms and the five categories, each followed by the source of genetic modification, the genetic variability via conventional breeding and the genetic distance:
Source: Nature Biotechnology, March 2003, vol 21, pp 227-228 Research news
The ideal alternative system for the production of monoclonal antibodies would be simple, scaleable, containable and economically attractive. Recently, researchers at La Jolla, Ca, developed a novel platform to synthesize antibodies in algal chloroplasts. This approach potentially meets all the criteria of an ideal alternative to animal cell culture. The authors expressed a large single-chain antibody against herpes simplex virus glycoprotein D in the chloroplast of the unicellular green alga Chlamydomonas reinhardtii. Antibody expression was driven by chloroplast-specific promoters. The ease with which green algae can be genetically engineered and grown, as well as their safety, makes them an attractive alternative to current antibody production methodologies. Source: Proc. Natl. Acad. Sci. USA 100, 438-442, 2003
Discovery gene of lethal form of skin cancer The incidence of the most aggressive form of skin cancer, melanoma, has doubled over the last 20 years in the U.S. Because malignant melanoma is generally unresponsive to chemotherapy, scientists are particularly interested in figuring out how it progresses and developing new means of treatment. Researchers have now identified a gene that causes melanoma in mice. In humans, the same gene is involved in a third of melanoma cases. http://sciam.rsc03.net/servlet/cc?lJpDWXXElJpPkpJhFmLkkHDLlE0EVX
Review: proteomic analysis A useful review titled 'Proteomic analysis of post-translational modifications' appeared recently in Nature Biotechnology (Matthias Mann and Ole Jensen). Classic techniques and mass spectrometry are used widely in the analysis of individual, purified proteins, but to characterize any single protein in complete detail is still a substantial research project, which by proteomic standards requires large amounts of protein and a combination of different techniques. The article reviews four different experimental approaches how to assess systematically the post-translational modifications of large numbers of proteins:
The authors end with the hope that once PTM analysis can routinely be done at the proteomic level, the involvement of PTM in disease can be studied much more systematically than has thus far been possible, and greater understanding of disease etiology will ultimately deliver many new targets for research against diseases. Source: Nature Biotechnology, March 2003, vol 21, pp 255-261).
Metabolic pathway engineering: new trick for yeast In a recent article it was described by Szczebara et al. how a yeast strain was equipped with an altered sterol pathway that can use a simple carbon source to synthesize hydrocortisone, an anti-inflammatory steroid hormone commonly used for the treatment of ailments such as arthritis, skin disorders and adrenal insufficiency. The altered pathway consists of 9 new genes and 4 gene deletions. Baker's yeast normally lacks the enzymatic machinery for synthesizing complex steroids. The authors managed the feat by combining heterologous gene expression of a single plant enzyme and eight mammalian proteins to mimic adrenal biosynthesis of hydrocortisone. Furthermore, four targeted gene deletions removed unwanted endogenous metabolic activity, while the yeast endogenous NADPH cytochrome P450 reductase was used to supply electrons to the mammalian CYPs. This work demonstrates the feasibility of transferring a complex biosynthetic pathway from higher eukaryotes into micro-organisms. Source: Nature Biotechnology February 2003, vol 21, pp 143-147
...and yeast also for antibody display Therapeutic and proteomics applications require the high throughput isolation of human antibodies. Recently, it was described how a large non-immune library of human single chain variable fragments of antibodies have been displayed on the surface of yeast. The authors used flow-cytometric and magnetic-bead screening methods to isolate the antibody fragments with nanomolar antigen-binding affinity. Key attributes of the yeast antibody library include the ability to amplify the library without measurable loss of clonal diversity and the capability to carry out simultaneous multiplex screens with at least a dozen different protein, peptide and hapten antigens. Source: Nature Biotechnology February 2003, vol 21, pp 163-166
The advent of meptides A number of seemingly unrelated neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, CJD and ALS have all recently been linked to a common pathogenic process called amyloidosis. In each case a specific peptide or protein clumps together in a specific part of the brain to form toxic soluble oligomers and/or insoluble fibres, which are widely believed to cause the progressive degenerations of neurons associated with these diseases. These oligomers and fibres are comprised of beta-sheets which form by association of peptides as extended beta-strands. Several academic groups and (at least) one biotech company are now working on a novel class of synthetic peptide derivatives (meptides) which can inhibit and reverse this process of protein/peptide aggregation in vitro. Meptides are virtually identical to natural peptides, except that they have methyl groups attached to the backbone nitrogen atoms of alternate amino acid residues. The methyl groups force the meptide molecule into the active beta-strand confirmation of a forming oligomer, but occupy only one edge of the beta-strand. The methyl groups block this edge of the molecule from associating with another beta-strand, while the other edge remains free. Consequently, the meptides are able to bind specifically to the peripheral strands of a growing beta-sheet and prevent its extension. These meptides have the potential to yield effective treatments or perhaps even outright cures for many of the neurodegenerative diseases mentioned earlier. They could make promising drug candidates because they are very small (MW approx 600 Da) and probably very non-immunogenic, are soluble and resistant to degradation.
Source: Kelvin Stott and Andrew Doig, European Biopharmaceutical Review, Spring 2003. Contact: Kelvin_stott@senexis.com and Andrew.doig@umist.ac.uk
Stem cell news
DG Research report on human embryonic stem cells research Commission Services (contact: Dr. Line Matthiessen) have released a report on the scientific, ethical, legal and socio-economic issues related to human embryonic stem cell research. The question on how to decide on EU funding for projects involving research with human embryonic stem cells was left open in decision-making process on the EU's FP6. The report reviews the potential benefits of human stem cell research and the pros and cons of using stem cells from different sources. It also reviews the current state of legislation in various EU member states and the governance of human stem cell research under FP6. The report provided the basis for an open and informed debate which took place on April 24. That debate will contribute to defining guidelines for EU-funded stem cell research. The report 'Commission staff working paper &endash; report on human embryonic stem cell research' (SEC(2003)441) is available on the secure part of the ACTIP website or may be downloaded from the EU's europa site: http://europa.eu.int/comm/research/conferences/2003/bioethics/index_en.html
Potent stem cells in baby teeth Your seven-year-old's baby tooth may be worth a lot more than the quarter the tooth fairy left under the pillow. Scientists have discovered that the pulp inside deciduous teeth is a treasure trove of fast-growing stem cells. Naturally-shed choppers could thus provide an easily accessible new source of these sought-after cells for clinical studies of stem-cell transplantation and tissue engineering. http://sciam.rsc03.net/servlet/cc?lJpDWXXElJpPkpJhFmLkkHDLlE0EVT
International stem cell project Discussions have begun on the possible creation of an international stem cell research consortium that aims to coordinate existing resources, such as human stem cell lines, in order to avoid duplication of research. Another aim is collaboration and assessment of each country's strengths. The initiative is promoted by the UK Medical Research Council. Countries possibly participating are the ones already funding such research: US, Canada, Australia, Finland, Sweden, Singapore and Israel. At present, the UK has the most favorable stem cell legislation, while US researchers have the most expertise in how stem cells specialize. Two expert working groups have been formed, one that will focus on the quality requirements to carry out stem cell research and the second to outline ethical rules in each country. Source: Nature Biotechnology, March 2003, vol 21, pp 220.
Neural commitment after ES monoculture Mouse embryonic stem cells are competent for production of all fetal and adult cell types, but their utility as a developmental model or as a source of defined cell populations for pharmaceutical screening or transplantation is limited because of poor control of differentiation in vitro. In a recent article, Ying and colleagues reported that neither multicellular aggregation nor coculture is necessary for mouse embryonic stem cells to commit efficiently to a neural fate. Using adherent monoculture, they eliminate inductive signals for alternative fates and thereby induced cells to develop into neural precursors. This process required autocrine fibroblast growth factor. Source: Nature Biotechnology, February 2003, vol 21, pp 183-186
Cryopreservation stem cells Company CryoCell Europe started two years ago with the cryopreservation of stem cells from cord blood for autologous use. In the US, the activity, which started there eight years ago, is a great success, with 25,000 of the annual 50,000 samples banked in the USA handled by CryoCell. In Europe, so far there have been 6,000 samples stored. However, CryoCell Europe has a wider scope than its American counterpart: it recently acquired German company MainGen in Frankfurt, which has a lot of know-how in the area of stem cell technology. CryoCell Europe is also involved in a large Multicenter (33) clinical trial whereby stem cells from bone marrow are injected into patients with an acute myocardial infarct. So far, the results are promising, with the heart's condition improving to the pre-infarct level. Source: Management Info 2003
New stem cell biology partnership On April 8, US company VistagenTherapeutics announced the signing of a strategic research partnership with Sanwa Kagaku Kenkyusho Co. Ltd., ("SKK"), an established international pharmaceutical company headquartered in Nagoya, Japan. Under the new agreement, both companies will utilize VistaGen's portfolio of stem cell technologies to develop innovative stem cell based discovery tools for internal research programs and commercialization with third parties. Terms of the agreement provide VistaGen with upfront technology license fees, an equity investment, and several years of funded research. Vistagen's stem cell technology platform is used for drug discovery, proteomics and in vitro toxicology. Business News
FDA: speed up marketing approvals At the end of January, FDA Commissioner Mark McClellan announced bold plans for speeding product reviews and approvals, including those for generic drugs, and indicated that these reforms will help to reduce costs for developing these products. The plan has three components: avoid multiple cycles of FDA review through early communication; adopt a quality systems approach to medical product reviews; provide product developers with up to date guidance for particular diseases and emerging technologies. As part of this initiative, FDA promises to clarify regulatory pathways in three areas: cell and gene therapy; pharmacogenomics, and novel drug delivery systems. Source: Nature Biotechnology. March 2003, vol 221, pp 219
Medicon Valley comes out top A new study from the Boston Consulting Group places the Denmark-Sweden 'Medicon Valley' among the best of Europe's Biotech Clusters. There are four major pharmaceutical corporations (Novo Nordisk, AstraZeneca, LEO Pharma and H. Lundbeck), and 115 life science companies &endash; of the latter, 55 have emerged since 1998. They have been nourished by the regions 12 universities (including the ones from Lund and Copenhagen), highly qualified pool of employees, and from clinical testing resources that are among the best in Europe. In total, 41,000 of the three million people living in the Medicon Valley region are employed in the life science industry. The Consultant's report found Medicon valley to be the world's best in terms of research for diabetes and highly attractive in three other commercially vibrant areas: immunology/inflammation, neuroscience and cancer. Furthermore, Medicon Valley has a higher number of partnerships and a greater incidence of partnerships per company than any other place in the world. The region is very active in pulling resources together. Here are some of the most prominent projects: Copenhagen BioCenter: a new research facility. Will be a strong cross-disciplinary environment. To be completed 2004; Biotech Research & Innovation Center (BRIC), Copenhagen: to be located within the BioCenter in 2005. Objective is to be a front-line, inter-disciplinary biotechnological research unit with focus on bioinformatics, gene expression, transgenic technology and functional analysis; Center for Stem Cell Biology and Cell Therapy, Lund: a multidisciplinary center for stem cell biology and cell therapy to be located at the BioMedical Center. Also new areas such as embryonic stem cells, functional stem cell genomics and non-mammalian stem cell biology. Center for diabetes and stem cell research, Lund: a multidisciplinary centre for diabetes research and stem cell research initiated by the Lund and Malmo University Hospitals. Focus on genetics, cell biology and pathophysiology of islets of Langerhans Swe-Gene-Proteomics Center, Lund: SweGene is a consortium within the field of functional genomics established by several Universities in Gotheborg and Lund. Purpose is to create common technology platforms and research centers in southwestern Sweden. Has a prominent proteomics centre in Lund.
Source:European Biopharmaceutical Review, Spring 2003. The report ëCommercial Attractiveness of Biomedical R&D in Medicon Valley' by The Boston Consulting group can be downloaded at www.mediconvalley.com
Top 10 Pharma deals in 2002 Globally there were 374 merger and acquisition deals in the pharma sector in 2002, but apart from the proposed megadeal between Pfizer-Pharmacia, (itself worth 60 billlion), the other deals together were worth only 11 billion, compared to 61 billion in the year 2001. Here are the top 10 deals in 2002:
Source: European Biopharmaceutical Review, Spring 2003 Publications
Pharma Market Authorization Strategies Launching a drug in Europe can be an extremely costly and time-consuming procedure, Although the centralized procedure is gaining ground as the one-stop shop for a EU-wide marketing authorization, its use is restricted to NCEs and biotechnology products. The majority of marketing authorizations are still issued by national competent authorities through the mutual recognition procedure. Pharma Market Authorization Strategies: A guide to launching drugs quickly and efficiently in Europe is a practical guide to speeding the process of launching drugs in the European market, deciding where to market first and how to build and retain market share post-authorization. HYPERLINK 'http://www.the-infoshop.com/study/rb12675_pharma_market_toc.html' http://www.the-infoshop.com/study/rb12675_pharma_market_toc.html EFB 25 years The European Federation of Biotechnology will celebrate its 25th anniversary during the 11th European Congress on Biotechnology (ECB11, 24.-29 August 2003) in Basel. EFB and the Swiss organizers of ECB11 invite the biotechnology community to a congress dedicated to the most recent developments and achievements in modern biotechnology while aiming at bridging the gaps and promoting the open dialogue between
For further information please visit www.ecb11.ch' www.ecb11.ch ! AGENDAA number of interesting conferences and workshops is coming up. Of all the events mentioned here, the detailed programmes and registration/application forms are available from the ACTIP secretariat.
Collaborations
and partnerships in the pharmaceutical &
biotech industries Genetics.
Genomes, the linkage to life 11th European
Congress on Biotechnology, 25th anniversary of
EFB: EuroScience
Open Forum 2004(ESOF2004 6th
Conference on Protein Expression in Animal
Cells Strategic
Resource management BioValley
Life Sciences Week Epidos Annual
Conference CORDIA-EuropaBio
Convention 2003 BioSquare
2004
ACTIP bulletin no. 34, June 2003
|
Home | Objectives | Organization | Members | News and Info. | Publications | Products | Interesting Links | Library | Secure